Last reviewed · How we verify
Phosphocreatine
Phosphocreatine is a Small molecule drug developed by Università Vita-Salute San Raffaele. It is currently in Phase 3 development.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Phosphocreatine |
|---|---|
| Sponsor | Università Vita-Salute San Raffaele |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy (NA)
- The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients (PHASE3)
- Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression (PHASE3)
- High-resolution Phosphocreatine and Creatine Mapping of Human Muscle and Brain
- Exercise Intolerance and Skeletal Muscle Bioenergetics in Children With Deep Venous Thrombosis (NA)
- Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease
- Skeletal Muscle Mitochondria in Ageing
- Rapid Improvement of Depression of Fluoxetine Combined With ATP (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phosphocreatine CI brief — competitive landscape report
- Phosphocreatine updates RSS · CI watch RSS
- Università Vita-Salute San Raffaele portfolio CI
Frequently asked questions about Phosphocreatine
What is Phosphocreatine?
Who makes Phosphocreatine?
What development phase is Phosphocreatine in?
Related
- Manufacturer: Università Vita-Salute San Raffaele — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing